Gilead bid against itself in $4.3B deal for CymaBay, filing shows

Gilead Sciences was the sole bidder for liver disease biotech CymaBay Therapeutics and ultimately hiked up its initial proposal by $9.50 per share, according to a new securities filing from Feb. 23.

Like many of the biopharma acquisitions in recent memory, CymaBay’s pending Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks